By analyzing existing fundamental indicators between OncorusInc and JPMorgan, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in JPMorgan with a short position in OncorusInc. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets.
One of the ways to look at asset utilization of OncorusInc is to check how much profit was generated for every dollar of assets it reports. OncorusInc holds a negative application of assets of -0.28 pct., losing $0.002756 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of OncorusInc shows how discouraging it operates for each dollar spent on its assets.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two entities, such as Oncorus or Altamira is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.
How important is Oncorus's Liquidity
Oncorus
financial leverage refers to using borrowed capital as a funding source to finance Oncorus ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Oncorus financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Oncorus' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Oncorus' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Oncorus's total debt and its cash.
Correlation Between Oncorus and Altamira Therapeutics
In general, Delisted Stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Oncorus together with similar or unrelated positions with a negative correlation. For example, you can also add Altamira Therapeutics to your portfolio. If Altamira Therapeutics is not perfectly correlated to Oncorus it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Oncorus, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Are you currently holding both Oncorus and Altamira Therapeutics in your portfolio? Please note if you are using this as a pair-trade strategy between Oncorus and Altamira Therapeutics, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses. Please check
pair correlation details between ONCR and CYTO for more information.
Is Oncorus valued sensibly by the market?
Cash and Equivalents Breakdown
Lets now check OncorusInc cash and equivalents. In accordance with the recently published financial statements, OncorusInc has 100.24
M in Cash and Equivalents. This is 87.79% lower than that of the Healthcare sector and 77.58% lower than that of the
Biotechnology industry. The cash and equivalents for all United States stocks is 96.29% higher than that of OncorusInc. As for JPMorgan Chase we see cash and equivalents of 1430
B, which is much higher than that of the Biotechnology
| ONCR | 100.24 Million | 0.007007 |
| Sector | 447.12 Million | 0.0313 |
| JPM | 1.43 Trillion | 99.96 |
Over 3 percent fall for OncorusInc. What does it mean for retail investors?
Latest maximum drawdown is at 23.04.
OncorusInc exhibits very low volatility with skewness of 0.0 and kurtosis of -0.14. However, we advise investors to further study OncorusInc technical indicators to ensure that all market info is available and is reliable. OncorusInc is a potential penny stock. Although OncorusInc may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in OncorusInc. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on OncorusInc instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
Our Conclusion on OncorusInc
While many other companies in the biotechnology industry are either recovering or due for a correction, OncorusInc may not be performing as strong as the other in terms of long-term growth potentials. The bottom line, as of the 17th of May 2023, our analysis shows that OncorusInc almost mirrors the market. The enterprise is
overvalued and projects
very high odds of distress for the next 2 years. Our current 90 days buy-or-sell advice on the enterprise is
Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Oncorus. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
